Decaffeinated Coffee Consumption Research Articles

Abstract 6470: Coffee and tea consumption, coffee-related metabolites, and breast cancer risk in US Women

Abstract Background: Coffee intake may protect against breast cancer; however, previous studies have been inconsistent and potential underlying mechanisms remain unclear. We aimed to 1) examine the association between total coffee, tea, and caffeine intake and breast cancer risk and 2) identify plasma metabolites associated with coffee intake and examine these metabolites in relation to breast cancer risk. Methods: Data on breast cancer risk factors were collected from questionnaires administered biennially and at the time of blood collections (Nurses’ Health study, NHS, distant collection: 1989-1990, recent collection: 2000-2002; NHSII, 1996-1999). We evaluated the association between total coffee (caffeinated and decaffeinated), tea consumption and caffeine intake and breast cancer risk in the full cohort using Cox regression models. Leveraging dietary and metabolomic data, we identified and validated plasma metabolites associated with coffee intake in 2,033 women from the NHSII breast cancer sub-study. We then evaluated the prospective association of all prior (PMID: 32788283) and new coffee-related metabolites with breast cancer risk in a nested case-control study using conditional logistic regression models. Results: We documented 10,060 cases of invasive breast cancer during 3,901,211 person-years of follow-up. In pooled, multivariable-adjusted models, compared to never consumers (0 cups/d), women consuming ≥6 cups/d of total coffee were at lower risk of invasive breast cancer (HR, 0.91; 95% CI, 0.82, 1.00; P-trend<0.01). Stratified analysis showed a significant effect modification by BMI (P-interaction=0.03). Compared to never consumers, drinking ≥6 cups of coffee per day was inversely associated with risk of invasive breast cancer among lean women (HR, 0.83; 95% CI, 0.72, 0.97) but not among overweight or obese women. Moreover, a lower risk of ER-negative breast cancer was observed with total coffee (HR ≥6 cups/d vs. 0 cups/day 0.75; 95% CI, 0.59, 0.95; P-trend=0.01) and decaffeinated coffee consumption (HR ≥4 cups/d vs. o cups/day 0.66; 95% CI, 0.45, 0.95; P-trend=0.01). Among the 31 studied metabolites, no single metabolite was associated with breast cancer risk. Associations were generally consistent between ER-positive and ER-negative breast cancer, although trigonelline seemed to be suggestively stronger for ER-negative (OR, 95% CI, 0.87, 0.75-1.01; P-value=0.061). Furthermore, 1,7-dimethyluric acid, some cholesterol esters (C18:1 CE, C18:2 CE and C20:4 CE) and trigonelline, all positively associated with coffee, were indicative of an inverse association with breast cancer risk among lean women. Conclusions: Coffee consumption was associated with lower breast cancer risk, particularly among lean women and ER-negative breast cancer. Some metabolites that might explain some of the observed inverse associations. Nonetheless, these results merit further exploration. Citation Format: Andrea Romanos-Nanclares, Oana A. Zeleznik, Mingyang Song, Walter C. Willett, Rulla M. Tamimi, Wendy Y. Chen, Michelle D. Holmes, Jae Hee Kang, A. Heather Eliassen. Coffee and tea consumption, coffee-related metabolites, and breast cancer risk in US Women [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 6470.

Coffee and caffeine intake and depression in postpartum women: A cross-sectional study from the National Health and Nutrition Examination Survey 2007-2018.

This cross-sectional study examines the association between coffee and caffeine consumption and depressive symptoms in postpartum women. In total, 821 postpartum women who met the study's inclusion criteria were interviewed. Data were extracted from the 2007-2018 National Health and Nutrition Examination Survey. Coffee consumption and 11 confounding variables were considered and analyzed as baseline data. Weighted logistic regression models were constructed by adjusting the variables, and the odds ratios of total coffee, caffeinated coffee, and decaffeinated coffee were assessed for their impact on depression status. In addition, subgroup analyses were conducted according to race, breastfeeding status, and postpartum period. The results show that generic coffee and caffeinated coffee intake have a potentially protective effect in postpartum women. Drinking more than three cups of caffeinated coffee may lower the risk of postpartum depression, particularly in the 1-2 year postpartum period and in non-breastfeeding women. The association between decaffeinated coffee consumption and postpartum depression remains unclear.

Increase from low to moderate, but not high, caffeinated coffee consumption is associated with favorable changes in body fat

Higher consumption of coffee and caffeine has been linked to less weight gain and lower body mass index in prospective cohort studies. The aim of the study was to longitudinally assess the association of changes in coffee and caffeine intake with changes in fat tissue, in particular, visceral adipose tissue (VAT) using dual x-ray absorptiometry (DXA). In the setting of a large, randomized trial of Mediterranean diet and physical activity intervention, we evaluated 1483 participants with metabolic syndrome (MetS). Repeated measurements of coffee consumption from validated food frequency questionnaires (FFQ) and DXA measurements of adipose tissue were collected at baseline, 6 months, 12 months and 3 years of follow-up. DXA-derived measurements of total and regional adipose tissue expressed as % of total body weight were transformed into sex-specific z-scores. Linear multilevel mixed-effect models were used to investigate the relationship between changes in coffee consumption and corresponding concurrent changes in fat tissue during a 3-year follow-up. After adjustment for intervention group, and other potential confounders, an increase in caffeinated coffee consumption from no or infrequent consumption (≤3 cups/month) to moderate consumption (1-7 cups/week) was associated with reductions in total body fat (Δ z-score:-0.06; 95% CI:-0.11 to-0.02), trunk fat (Δ z-score:-0.07; 95% CI:-0.12 to-0.02), and VAT (Δ z-score:-0.07; 95% CI:-0.13 to-0.01). Neither changes from no or infrequent consumption to high levels of caffeinated coffee consumption (>1 cup/day) nor any changes in decaffeinated coffee consumption showed significant associations with changes in DXA measures. Moderate changes in the consumption of caffeinated coffee, but not changes to high consumption, were associated with reductions in total body fat, trunk fat and VAT in a Mediterranean cohort with MetS. Decaffeinated coffee was not linked to adiposity indicators. Moderate consumption of caffeinated coffee may be part of a weight management strategy. The trial was registered at the International Standard Randomized Controlled Trial (ISRCTN: http://www.isrctn.com/ISRCTN89898870) with number 89898870 and registration date of 24 July 2014, retrospectively registered.

Association between coffee intake and frailty among older American adults: A population-based cross-sectional study.

We aimed to investigate the association between coffee consumption and frailty in older American adults. We focused on individuals at higher frailty risk, such as women, ethnic minorities, smokers, and those with obesity and insufficient physical activity. The data of 8,087 individuals aged over 60 years from the 2007-2018 National Health and Nutrition Examination Surveys were used for this cross-sectional study. The coffee drinks were classified into two categories: caffeinated and decaffeinated. Frailty was measured using the 53-item frailty index. Weighted binary logistic regression was used to evaluate the association between coffee intake and frailty risk. Restricted cubic spline models were used to assess the dose-response relationship between caffeinated coffee intake and frailty. Among the 8,087 participants, 2,458 (30.4%) had frailty. Compared with those who reported no coffee consumption, the odds ratios [ORs; 95% confidence intervals (CIs)] of total coffee consumption > 498.9 (g/day) were 0.65 (0.52, 0.79) in the fully adjusted model. Compared with those who reported no caffeinated coffee consumption, the ORs (95% CIs) of total coffee consumption > 488.4 (g/day) were 0.68 (0.54, 0.85) in the fully adjusted model. Compared with those who reported no decaffeinated coffee consumption, the ORs (95% CIs) of total coffee consumption > 0 (g/day) were 0.87 (0.71, 1.06) in the fully adjusted model. Nonlinear associations were detected between total coffee and caffeinated coffee consumption and frailty. In the subgroup analyses by smoking status, the association between coffee consumption and the risk of frailty was more pronounced in non-smokers (P for interaction = 0.031). Caffeinated coffee consumption was independently and nonlinearly associated with frailty, especially in non-smokers. However, decaffeinated coffee consumption was not associated with frailty.

Dose-response relationships of tea and coffee consumption with gout: a prospective cohort study in the UK Biobank.

The association of tea or coffee consumption with gout is inconsistently reported. Few prospective studies have explored their dose-response relationship. Therefore, we aimed to quantitatively investigate the association between tea, coffee and the risk of developing gout. The study included 447 658 participants in the UK Biobank who were initially free of gout. Tea and coffee consumption were assessed at baseline. We used Cox proportional hazards models to estimate the associations between tea/coffee consumption and incident gout, with restricted cubic spline added to the Cox models to evaluate the dose-response relationships. During a median follow-up period of 13.42 years, we recorded 3,053 gout cases. The associations between tea, coffee and gout were nonlinear, with a significant reduction in the risk by ∼ six cups/day of tea and three cups/day of coffee. Compared with those who were not tea and coffee drinkers, those who consumed >6 cups/day of tea or coffee were associated with 23% (HR 0.77, 95% CI, 0.66, 0.91) and 40% (HR 0.60, 95% CI, 0.47, 0.77) lower risks of gout, respectively, and both caffeinated and decaffeinated coffee consumption were associated with a decreased risk. Moreover, hyperuricaemia may modify the association between coffee and gout. Compared with non-coffee consumers with hyperuricaemia, those with ≥4 cups/day coffee intake without hyperuricaemia had the lowest risk (HR 0.34, 95% CI, 0.28, 0.41). Consumption of tea or coffee had a strong nonlinear association in gout risk reduction. Hyperuricaemia status had a potential effect modification on the association of coffee intake with gout.

Association between Coffee Consumption, Caffeine Intake, and Metabolic Syndrome Severity in Patients with Self-Reported Rheumatoid Arthritis: National Health and Nutrition Examination Survey 2003-2018.

Rheumatoid arthritis (RA) is chronic inflammatory disease. Although coffee impacts metabolism, no evidence has shown an association between coffee consumption and decreased risk for developing metabolic syndrome (MetS) among RA patients. Hence, we examined the association between coffee consumption and metabolic syndrome severity among 1094 participants with self-reported RA. Accordingly, patients with MetS z-scores of <0 and ≥0 were designated as low- and high-risk groups, respectively. In the fully adjusted model, drinking over two cups of coffee daily was associated with a decrease in the MetS z-score (p = 0.04). Subgroup analysis showed that in the low-risk group, daily intake of <2 cups of coffee was associated with low MetS z-scores (p = 0.003), scores (p = 0.03). Coffee intake was associated with low body mass index (p = 0.03 for 0−2 cups per day; p = 0.02 for >2 cups per day) and low HOMA-IR (β, −2.62; 95%CI, −5.13 to −0.11; p = 0.04). Our study suggests that coffee, but not decaffeinated coffee consumption and total caffeine intake, is associated with MetS severity in RA.

Morphological changes in retinochoroidal microvasculature after caffeinated versus decaffeinated coffee consumption

BackgroundTo investigate changes in retinochoroidal microvascular morphology after caffeinated versus decaffeinated coffee consumption in age- and gender-matched healthy individuals using optical coherence tomography (OCT) and OCT angiography (OCTA). MethodsIn this prospective, randomized clinical study, a staff member in charge of record keeping randomly assigned 48 healthy volunteers to two groups: caffeinated coffee consumers (24 eyes) and decaffeinated coffee consumers (24 eyes). Participants' ages and genders were recorded before consumption, and a comprehensive ophthalmologic exam was performed, followed by OCT and OCTA analyses before, 30 min, one, six, and 24 h after blindly consuming either of the coffees. ResultsCaffeinated and decaffeinated coffee consumers had mean ages of 23.45 ± 0.92 and 22.73 ± 1.13, respectively (p = 0.407). The following parameters changed significantly in caffeinated coffee consumers 30 min and 1 h post-consumption (pre-consumption versus 30 min versus one hour post-consumption; p < 0.05): a) parafoveal superficial capillary plexus vessel density (%): 54.45 versus 51.8 versus 51.92, b) parafoveal deep capillary plexus vessel density (%): 55.16 versus 52.45 versus 52.83, c) outer retinal flow area (%): 8.87 ± 1.91 versus 8.03 ± 1.88 versus 8.11 ± 1.93, d) choriocapillaris flow area (mm2): 20.95 ± 0.98 versus 19.82 ± 1.20 a versus 19.62 ± 0.95, and e) sub-foveal choroidal thickness (µm): 295.06 ± 5.45 versus 277.08 ± 5.33 versus 260.71 ± 58.61. No significant differences in any OCT and OCTA parameters were found between consecutive measurements in decaffeinated coffee consumers (p > 0.05). ConclusionsCaffeinated coffee appears to transiently reduce parafoveal vessel density, capillary flow area, and sub-foveal choroidal thickness. Lack of these microvascular morphological changes in decaffeinated coffee suggests a potential caffeine-induced vasoconstrictive effect.

Shared Genetics and Causality Between Decaffeinated Coffee Consumption and Neuropsychiatric Diseases: A Large-Scale Genome-Wide Cross-Trait Analysis and Mendelian Randomization Analysis

Coffee or caffeine consumption has been associated with neuropsychiatric disorders, implying a shared etiology. However, whether these associations reflect causality remains largely unknown. To understand the genetic structure of the association between decaffeinated coffee consumption (DCC) and neuropsychiatric traits, we examined the genetic correlation, causality, and shared genetic structure between DCC and neuropsychiatric traits using linkage disequilibrium score regression, bidirectional Mendelian randomization (MR), and genome-wide cross-trait meta-analysis in large GWAS Consortia for coffee consumption (N = 329,671) and 13 neuropsychiatric traits (sample size ranges from 36,052 to 500,199). We found strong positive genetic correlations between DCC and lifetime cannabis use (LCU; Rg = 0.48, P = 8.40 × 10−19), alcohol use disorder identification test (AUDIT) total score (AUDIT_T; Rg = 0.40, P = 4.63 × 10−13), AUDIT_C score (alcohol consumption component of the AUDIT; Rg = 0.40, P = 5.26 × 10−11), AUDIT_P score (dependence and hazardous-use component of the AUDIT; Rg = 0.28, P = 1.36 × 10−05), and strong negative genetic correlations between DCC and neuroticism (Rg = −0.15, P = 7.27 × 10−05), major depressed diseases (MDD; Rg = −0.15, P = 0.0010), and insomnia (Rg= −0.15, P = 0.0007). In the cross-trait meta-analysis, we identified 6, 5, 1, 1, 2, 31, and 27 shared loci between DCC and Insomnia, LCU, AUDIT_T, AUDIT_C, AUDIT_P, neuroticism, and MDD, respectively, which were mainly enriched in bone marrow, lymph node, cervix, uterine, lung, and thyroid gland tissues, T cell receptor signaling pathway, antigen receptor-mediated signaling pathway, and epigenetic pathways. A large of TWAS-significant associations were identified in tissues that are part of the nervous system, digestive system, and exo-/endocrine system. Our findings further indicated a causal influence of liability to DCC on LCU and low risk of MDD (odds ratio: 0.90, P = 9.06 × 10−5 and 1.27, P = 7.63 × 10−4 respectively). We also observed that AUDIT_T and AUDIT_C were causally related to DCC (odds ratio: 1.83 per 1-SD increase in AUDIT_T, P = 1.67 × 10−05, 1.80 per 1-SD increase in AUDIT_C, P = 5.09 × 10−04). Meanwhile, insomnia and MDD had a causal negative influence on DCC (OR: 0.91, 95% CI: 0.86–0.95, P = 1.51 × 10−04 for Insomnia; OR: 0.93, 95% CI: 0.89–0.99, P = 6.02 × 10−04 for MDD). These findings provided evidence for the shared genetic basis and causality between DCC and neuropsychiatric diseases, and advance our understanding of the shared genetic mechanisms underlying their associations, as well as assisting with making recommendations for clinical works or health education.

Effects of Caffeinated and Decaffeinated Coffee Consumption on Metabolic Syndrome Parameters: A Systematic Review and Meta-Analysis of Data from Randomised Controlled Trials.

Coffee is rich in phenolic acids, such as caffeic acid and chlorogenic acid (CGA). Polyphenol-rich diets were shown to reduce the risk of metabolic syndrome (MeTS). Background and Objectives: This systematic review and meta-analysis discusses the effects of coffee consumption and its dose-response on MeTS parameters. Materials and Methods: PubMed and Scopus® were searched for relevant articles published between 2015 and 2020. This review focused on randomised controlled trials (RCTs) investigating the effect of coffee consumption on anthropometric measurements, glycaemic indices, lipid profiles, and blood pressure. Data from relevant studies were extracted and analysed using random, fixed, or pooled effects models with 95% confidence intervals (CIs). Results: Green coffee extract (GCE) supplementation (180 to 376 mg) was found to reduce waist circumference (weighted mean difference (WMD) = −0.39; 95% CI: −0.68, −0.10), triglyceride levels (WMD = −0.27; 95% CI: −0.43, −0.10), high−density lipoprotein−cholesterol levels (WMD = 0.62; 95% CI: 0.34, 0.90), systolic blood pressure (WMD = −0.44; 95% CI: −0.57, −0.32), and diastolic blood pressure (WMD = −0.83; 95% CI: −1.40, −0.26). Decaffeinated coffee (510.6 mg) reduced fasting blood glucose levels (WMD = −0.81; 95% CI: −1.65, 0.03). The meta-analysis showed that the intake of GCE containing 180 to 376 mg of CGA (administered in a capsule) and liquid decaffeinated coffee containing 510.6 mg of CGA improved the MeTS outcomes in study participants. Conclusions: The findings of the review suggested that the effect of coffee on MeTS parameters varies depending on the types and doses of coffee administered. A more detailed RCT on specific coffee doses (with adjustment for energy and polyphenol intake) and physical activity is needed to further confirm the observed outcomes.

278 Caffeinated or decaffeinated coffee consumption and risk of cancers: A meta-analysis

278 Caffeinated or decaffeinated coffee consumption and risk of cancers: A meta-analysis

Coffee Consumption and All-Cause, Cardiovascular, and Cancer Mortality in an Adult Mediterranean Population.

We assessed the association between usual coffee consumption and all-cause, cardiovascular (CV), and cancer mortality in an adult population in Spain, taking into account both the amount and type of coffee consumed. We used baseline data on coffee consumption and other personal variables, and the number of deaths during an 18-year follow-up period, for 1567 participants aged 20 years and older from the Valencia Nutrition Study in Spain. Total, caffeinated, and decaffeinated coffee consumption was assessed using a validated food frequency questionnaire. Cox regression models were used to estimate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs). During the 18-year follow-up period, 317 died; 115 due to CV disease and 82 due to cancer. Compared with no-consumption, the consumption of ≤1 cup per day and >1 cup per day of coffee was associated with a lower risk of all-cause mortality, HR = 0.73 (95% CI: 0.56–0.97) and HR 0.56 (95% CI: 0.41–0.77), respectively. A lower cancer mortality was observed among drinkers of more than 1 cup per day compared with nondrinkers, HR 0.41 (95% CI 0.20–0.86). Regarding the type of coffee, only the overall consumption of caffeinated coffee was associated with lower all-cause mortality at 12 and 18 years of follow-up, HR = 0.66 (95% CI:0.46–0.94) and HR = 0.59 (95% CI: 0.44–0.79), respectively. In conclusion, this study suggests that the moderate consumption of coffee, particularly caffeinated coffee (range 1–6.5 cups per day), is associated with a lower all-cause and cancer mortality after a long follow-up period. No significant association was found between coffee consumption and CVD mortality.

Coffee Consumption and Invasive Breast Cancer Incidence among Postmenopausal Women in the Cancer Prevention Study-II Nutrition Cohort

There is limited evidence of a potential inverse association between coffee, particularly caffeinated coffee, consumption and postmenopausal breast cancer risk, and few studies have examined this association by tumor hormone receptor status. To provide further evidence, we examined total, caffeinated, and decaffeinated coffee consumption in relation to postmenopausal invasive breast cancer incidence overall, and by tumor estrogen receptor (ER) and/or progesterone receptor (PR) subtype. Among 57,075 postmenopausal women in the Cancer Prevention Study-II Nutrition Cohort who were cancer free and reported coffee intake in 1999, we identified 2,980 women diagnosed with invasive breast cancer during follow-up through June 2015. Multivariable-adjusted Cox proportional hazards regression was used to compute hazard ratios (HR) and 95% confidence intervals (CI). Neither total, caffeinated, nor decaffeinated coffee consumption was associated with invasive breast cancer risk; HRs (95% CIs) comparing consumption of ≥2 cups per day with <1 cup per month were 0.99 (0.89-1.11), 0.96 (0.87-1.06), and 1.06 (0.95-1.19), respectively. Similarly, coffee consumption was not associated with risk of hormone receptor-positive (ER+ or PR+) or hormone receptor-negative (ER- and PR-) breast tumors. These findings do not support an association between coffee consumption and invasive breast cancer risk among postmenopausal women. This large prospective study contributes to the limited evidence on coffee consumption and breast cancer risk, finding no association overall or by tumor receptor subtype.

Association between coffee consumption and total dietary caffeine intake with cognitive functioning: cross-sectional assessment in an elderly Mediterranean population.

Coffee is rich in compounds such as polyphenols, caffeine, diterpenes, melanoidins and trigonelline, which can stimulate brain activity. Therefore, the possible association of coffee consumption with cognition is of considerable research interest. In this paper, we assess the association of coffee consumption and total dietary caffeine intake with the risk of poor cognitive functioning in a population of elderly overweight/obese adults with metabolic syndrome (MetS). PREDIMED-plus study participants who completed the Mini-Mental State Examination test (MMSE) (n = 6427; mean age = 65 ± 5years) or a battery of neuropsychological tests were included in this cross-sectional analysis. Coffee consumption and total dietary caffeine intake were assessed at baseline using a food frequency questionnaire. Logistic regression models were fitted to evaluate the association between total, caffeinated and decaffeinated coffee consumption or total dietary caffeine intake and cognitive impairment. Total coffee consumers and caffeinated coffee consumers had better cognitive functioning than non-consumers when measured by the MMSE and after adjusting for potential confounders (OR 0.63; 95% CI 0.44-0.90 and OR 0.56; 95% CI 0.38-0.83, respectively). Results were similar when cognitive performance was measured using the Clock Drawing Test (CDT) and Trail Making Test B (TMT-B). These associations were not observed for decaffeinated coffee consumption. Participants in the highest tertile of total dietary caffeine intake had lower odds of poor cognitive functioning than those in the reference tertile when screened by the MMSE (OR 0.64; 95% CI 0.47-0.87) or other neurophysiological tests evaluating a variety of cognitive domains (i.e., CDT and TMT-A). Coffee consumption and total dietary caffeine intake were associated with better cognitive functioning as measured by various neuropsychological tests in a Mediterranean cohort of elderly individuals with MetS. ISRCTN89898870. Registration date: July 24, 2014.

Regular Coffee Consumption Is Associated with Lower Regional Adiposity Measured by DXA among US Women

Coffee is among the most popular daily beverages in the United States. Importantly, coffee consumption has been associated with a lower risk of multiple health outcomes including a reduction in adiposity. DXA is a means to assess body fat and distribution. The aim of this study was to examine the relation between coffee consumption and DXA-assessed adiposity and adiposity distribution. Cross-sectional data from the NHANES were used. Participants were adults aged 20-69 y from the 2003-2004 and 2005-2006 waves. Information on coffee consumption was assessed through the FFQ (categorized as no coffee, 0 to <0.25 cup/d, 0.25 to <1 cup/d, 1 cup/d, 2-3 cups/d, or ≥4 cups/d). Both caffeinated and decaffeinated coffee consumption were included. Trunk fat and total fat percentage were measured via whole-body DXA scans. The association between coffee consumption and body fat was investigated using age-adjusted and multivariable-adjusted linear regression models which accounted for sample weights. Higher coffee consumption was associated with significantly lower total body fat percentage and trunk body fat percentage in a dose-response manner (all P values<0.05) among women. Although this dose-response relation was nonsignificant among men, men aged 20-44 y who drank 2-3 cups/d had 1.3% (95% CI: -2.7%, 0.1%) less total fat and 1.8% (95% CI: -3.3%, -0.4%) less trunk fat than those who did not consume coffee. Furthermore, the association between coffee consumption and body fat percentage exhibited for both caffeinated and decaffeinated coffee among women (all P for trend<0.001) but not among men (all P for trend>0.05). The present study found a significant association between higher coffee consumption and lower DXA-measured adiposity. Moreover, a gender difference in this association in the general US adult population was also observed.

Decaffeinated Coffee Consumption and Renal Function Impairment in Health and Diabetes: A Paradigm-Shift

Aim: The belief that decaffeinated coffee (DCAF) does not contain a physiologically relevant concentration of caffeine and therefore has no significant adverse effect on renal endpoints makes patients who are vulnerable to renal dysfunction, renal compromised state, medical conditions that contraindicate caffeine intake or those already on prescription medications known to adversely affect the kidney to sometimes substitute DCAF for caffeinated coffee even as the credibility of this paradigm remains disputable. Therefore, the present study aimed to assess the effect of DCAF consumption on markers of renal function and carbohydrate metabolism in health and diabetes. Materials and Methods: Sixty Wistar Albino rats were divided into 12 groups (6pairs) (n=5per group) for male and female animals. Animals in group 1 served as normal control (NCTRL) and were given standard feed and water only. Animals in group 2 received standard feed plus DCAF. Group 3 was the diabetic (DIA) only group while groups 4, 5, and 6 were DIA plus DCAF treatment groups. After 4weeks of treatment, animals were sacrificed and blood obtained and analyzed for the biochemical indices of renal function and carbohydrate metabolism using standard methods. Results: Serum creatinine (SCr) levels increased significantly in all DCAF treated groups compared with the NCTRL group in male and female animals. Serum electrolytes did not show any significant change across groups. Serum Urea (SUr) increased and decreased in DIA alone group and DIA plus DCAF groups respectively. Serum glucose, insulin, and HOMA-IR increased and decreased significantly in DIA alone group and DIA plus DCAF treated groups respectively compared with NCTRL and DCAF control groups. Conclusion: The consumption of DCAF may adversely affect renal endpoints in health and diabetes but improves markers of carbohydrate metabolism in diabetes likely due to the re-enforcement effect of its caffeine and other bioactive constituents.

Coffee Consumption and Mortality Among US Adults: A Cohort Study

Abstract Objectives Coffee is a commonly consumed beverage in the United States (US). It remains controversial whether coffee consumption is associated with health benefits or harms, especially when cream and/or sugars are added. Methods We assessed coffee consumption in association with mortality outcomes among 36,758 US adults ages 20+ years who participated in the National Health and Nutrition Examination Survey (NHANES) 1999–2014. Consumption of total, caffeinated, and decaffeinated coffee, with and without additives, was assessed using dietary data collected from 24-hour diet recalls (24HR) and compared to coffee consumption assessed using a food-frequency questionnaire (FFQ). Mortalities from all causes, heart disease, and cancer were obtained from linkage to the National Death Index through December 31, 2015. We used Cox proportional hazard models to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) after multivariable adjustments. Results The mean (SE) of the total, caffeinated, and decaffeinated coffee consumption among US adults was 1.36 (0.02), 1.19 (0.02), and 0.17 (0.004) cups/day, respectively. The Spearman correlation coefficient on coffee consumption for a subset of participants with both 24HR and FFQ is 0.78 (P-value &amp;lt; 0.0001). During a median follow-up of 7.4 years, a total of 4662 deaths occurred due to all causes, including 794 deaths due to heart disease and 1019 deaths due to cancer. Compared to individuals who were not usual coffee drinkers (&amp;lt;1 cup/d), those who drank coffee for 1 cup/day or more had a lower risk of all-cause mortality (HR [95% CI]: 0.84 [0.76, 0.94] for ≥1 to &amp;lt;2 cups/d; 0.82 [0.72, 0.92] for ≥2 to &amp;lt;3 cups/d; and 0.80 [0.68, 0.93] for ≥3 cups/d; P-trend = 0.001]. Adding milk/cream, alone or with sugar/sweetener, did not significantly change the results. Similar patterns were observed for caffeinated coffee consumption and all-cause mortality, but no significant associations were found for decaffeinated coffee. Coffee consumption was not significantly associated with cancer or heart disease mortality except that moderate caffeinated coffee consumption (≥1 to &amp;lt;2 cups/d) was significantly associated with a lower risk of heart disease mortality [HR (95% CI): 0.72 (0.52, 0.98)]. Conclusions Usual coffee consumption was associated with a reduced risk of all-cause mortality among US adults. Funding Sources NIH/NIMHD.

Effect of Decaffeinated Coffee Consumption on Markers of Atherogenesis and Carbohydrate Metabolism in Diet-Induced Dyslipidemia in Rats

Effect of Decaffeinated Coffee Consumption on Markers of Atherogenesis and Carbohydrate Metabolism in Diet-Induced Dyslipidemia in Rats

Is Coffee a Useful Source of Caffeine Preexercise?

Caffeine is a well-established ergogenic aid, with its performance-enhancing effects demonstrated across a wide variety of exercise modalities. Athletes tend to frequently consume caffeine as a performance enhancement method in training and competition. There are a number of methods available as a means of consuming caffeine around exercise, including caffeine anhydrous, sports drinks, caffeine carbohydrate gels, and gum. One popular method of caffeine ingestion in nonathletes is coffee, with some evidence suggesting it is also utilized by athletes. In this article, we discuss the research pertaining to the use of coffee as an ergogenic aid, exploring (a)whether caffeinated coffee is ergogenic, (b)whether dose-matched caffeinated coffee provides a performance benefit similar in magnitude to caffeine anhydrous, and (c)whether decaffeinated coffee consumption affects the ergogenic effects of a subsequent isolated caffeine dose. There is limited evidence that caffeinated coffee has the potential to offer ergogenic effects similar in magnitude to caffeine anhydrous; however, this requires further investigation. Coingestion of caffeine with decaffeinated coffee does not seem to limit the ergogenic effects of caffeine. Although caffeinated coffee is potentially ergogenic, its use as a preexercise caffeine ingestion method represents some practical hurdles to athletes, including the consumption of large volumes of liquid and difficulties in quantifying the exact caffeine dose, as differences in coffee type and brewing method may alter caffeine content. The use of caffeinated coffee around exercise has the potential to enhance performance, but athletes and coaches should be mindful of the practical limitations.

Caffeine, Type of Coffee, and Risk of Ovarian Cancer: A Dose-Response Meta-Analysis of Prospective Studies.

Prospective studies on caffeine and different types of coffee intake in relation to the risk of ovarian cancer have shown conflicting results. The aim of the present study was to perform a dose-response meta-analysis of cohort studies on the association between dietary caffeine intake, different types of coffee consumption, and the risk of ovarian cancer. PubMed/Medline, ISI Web of Science, Scopus, and EMBASE were searched to identify relevant studies reported until October 2018. Prospective cohort studies that had considered caffeine or different types of coffee as the exposure variable and ovarian cancer as the main outcome variable or as one of the outcome variables were included in our systematic review and meta-analysis. Two of us independently screened 9344 publications. A total of 14 cohort studies were included in the meta-analysis. Two of us independently extracted the data. Any disagreements were resolved in consultation with the principal investigator. Combining 13 effect sizes, we found no substantial association between coffee consumption and risk of ovarian cancer [risk ratio (RR), 1.08; 95% CI, 0.89 to 1.33]. Also, one additional cup daily of coffee consumption was marginally associated with an increased risk of ovarian cancer (RR, 1.02; 95% CI, 0.99 to 1.05; P = 0.21; I2 = 0.0%; Pheterogeneity = 0.68). No statistically significant association was observed between caffeine intake or caffeinated or decaffeinated coffee consumption and the risk of ovarian cancer. We found no statistically significant association between caffeine intake or different types of coffee and the risk of ovarian cancer.

Abstract 966: Coffee consumption and invasive breast cancer incidence among postmenopausal women in the Cancer Prevention Study II Nutrition Cohort

Abstract Accumulating evidence suggests that coffee consumption may be inversely associated with breast cancer risk among postmenopausal women, with growing evidence of a stronger association for caffeinated than for decaffeinated coffee. However, few studies have examined this association by hormone receptor status or minimized confounding due to cigarette smoking. Recently, we found that caffeinated, but not decaffeinated coffee consumption was inversely associated with breast cancer mortality among nonsmoking women enrolled in the Cancer Prevention Study-II (CPS-II). Subsequently, the 2018 WCRF/AICR Diet, Nutrition, Physical Activity and Cancer Third Expert Report drew no conclusion regarding the association between coffee consumption and breast cancer risk. To provide further evidence, we examined total, caffeinated and decaffeinated coffee consumption in relation to postmenopausal invasive breast cancer incidence, overall, among nonsmokers and by estrogen and/or progesterone receptor (ER/PR) status among women enrolled in the CPS-II Nutrition Cohort, a subcohort of CPS-II. This analysis included 57,120 postmenopausal women who were cancer-free and reported coffee intake in 1999, and who were followed for cancer incidence through June 2013. During follow-up, 2,848 (2,349 ER or PR positive, and 252 ER and PR negative) women with a verified invasive breast cancer were identified. Cox proportional hazards regression was used to estimate multivariable-adjusted hazard ratios (HR) and 95% confidence intervals (CI). Neither total nor decaffeinated coffee consumption was associated with risk of invasive breast cancer among all women or in any subgroup. For caffeinated coffee consumption, the HR (95% CI) for consumption of 2 or more cups/day, compared to less than 1 cup/month, was 0.90 (0.82-1.00) among all women, and 0.88 (0.80-0.98) among nonsmokers. Similarly, caffeinated coffee consumption was associated with a statistically significantly lower risk of ER+ or PR+ breast cancer (HR=0.88, 95% CI 0.79-0.99) and a nonsignificant lower risk of ER- and PR- breast cancer (HR=0.83, 95% CI 0.59-1.16) among all women. These findings underscore the importance of stratifying on type of coffee in studies examining the association between coffee consumption and risk of invasive postmenopausal breast cancer. Additionally, to better understand the role of caffeinated vs. decaffeinated coffee in breast cancer etiology we will examine the potential mediating effects of coffee metabolites on this association. Citation Format: Susan M. Gapstur, Marjorie L. McCullough, Rebecca A. Hodge, Ying Wang, Caroline Y. Um, Terryl J. Hartman, Mia M. Gaudet. Coffee consumption and invasive breast cancer incidence among postmenopausal women in the Cancer Prevention Study II Nutrition Cohort [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 966.